Universe Pharmaceuticals receives notice from Nasdaq related to delayed annual report

• Universe Pharmaceuticals (NASDAQ:UPC) received a notice from Nasdaq that UPC is late in filing its annual report for the fiscal year ending September 30, 2024, which could lead to delisting.
• UPC is provided until February 26, 2025, to request a stay of the suspension of the company’s securities, pending a Hearings Panel decision.
• The company intends to request a stay of the suspension before that date.
• Source: Press release

More on Universe Pharmaceuticals

• Universe Pharmaceuticals receives Nasdaq delisting notice
• Universe Pharmaceuticals stock slides on capital raise of about $15M via securities offering
• Financial information for Universe Pharmaceuticals